All In Biotech

Drug Trial Radar · NCT02058147

Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM

A Randomized, 30 Week, Active-controlled, Open-label, 3-treatment Arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination to Insulin Glargine Alone and to Lixisenatide Alone on Top of Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)

Last checked: Nov 20, 2026Latest source record: May 9, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,170 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,170

Actual

Start

Feb 2014

Primary completion

Jun 2015

Study completion Jun 2015

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Feb 7, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To compare the insulin glargine/lixisenatide fixed ratio combination to lixisenatide alone and to insulin glargine alone (on top of metformin treatment) in glycated hemoglobin (HbA1c) change from baseline to Week 30. Secondary Objective: To compare the overall efficacy and safety of insulin glargine/lixisenatide fixed ratio combination (FRC) to insulin glargine alone and to lixisenatide alone (on top of metformin treatment) over a 30 week treatment period in participants with type 2 diabetes.

Conditions

  • Type 2 Diabetes

Interventions

  • Insulin glargine/lixisenatide Fixed Ratio CombinationDrug

    Insulin glargine/Lixisenatide FRC was self-administered by subcutaneous (SC) injection in the morning within one hour before breakfast using one of the 2 prefilled disposable SoloStar® pen-injectors: Pen A containing 100 U/mL insulin glargine (Lantus, 100 U/mL) and 50 mcg/mL lixisenatide in a ratio of 2 U:1 mcg, used for administration of doses from 10 U to 40 U (10 U/5mcg to 40 U/20mcg). Pen B containing 100 U/mL insulin glargine (Lantus, 100 U/mL) and 33 mcg/mL lixisenatide in a ratio of 3 U:1 mcg, used to administer doses from 41 U to 60 U (41 U/13 mcg to 60 U/20 mcg). The starting dose was 10 U/5 mcg. Dose was then adjusted individually to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L) while avoiding hypoglycemia.

  • Insulin glargine (HOE901)Drug

    Insulin glargine (100 U/mL) was self-administered by SC injection at approximately the same time every day. Dose was adjusted individually to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L) while avoiding hypoglycemia.

  • Lixisenatide (AVE0010)Drug

    Lixisenatide was self-administered by SC injection within 0 to 60 minutes before breakfast or evening meal. If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 10 mcg.

  • MetforminDrug

    Pharmaceutical form: Tablet; Route of administration: Oral administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1c From Baseline to Week 30Time frame: Baseline, Week 30

Locations

273 sites in 23 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 840027

    Phoenix, Arizona

  • Investigational Site Number 840122

    Phoenix, Arizona

  • Investigational Site Number 840062

    Tempe, Arizona

  • Investigational Site Number 840023

    Tempe, Arizona

  • Investigational Site Number 840084

    Little Rock, Arkansas

  • Investigational Site Number 840100

    Anaheim, California

  • Investigational Site Number 840065

    Bell Gardens, California

  • Investigational Site Number 840090

    Chino, California

  • Investigational Site Number 840002

    Chula Vista, California

  • Investigational Site Number 840013

    Concord, California

  • Investigational Site Number 840053

    Fresno, California

  • Investigational Site Number 840017

    La Jolla, California

  • Investigational Site Number 840070

    Lancaster, California

  • Investigational Site Number 840121

    Long Beach, California

  • Investigational Site Number 840126

    Los Angeles, California

  • Investigational Site Number 840044

    Los Angeles, California

  • Investigational Site Number 840101

    Mission Hills, California

  • Investigational Site Number 840086

    Mission Viejo, California

  • Investigational Site Number 840120

    Mission Viejo, California

  • Investigational Site Number 840005

    Northridge, California

  • Investigational Site Number 840034

    Palm Springs, California

  • Investigational Site Number 840074

    Port Hueneme, California

  • Investigational Site Number 840068

    San Ramon, California

  • Investigational Site Number 840067

    Santa Ana, California

  • Investigational Site Number 840029

    Tarzana, California

  • Investigational Site Number 840006

    Temecula, California

  • Investigational Site Number 840078

    West Hills, California

  • Investigational Site Number 840059

    Aurora, Colorado

  • Investigational Site Number 840038

    Denver, Colorado

  • Investigational Site Number 840104

    Bradenton, Florida

  • Investigational Site Number 840098

    Miami, Florida

  • Investigational Site Number 840014

    New Port Richey, Florida

  • Investigational Site Number 840047

    Ocoee, Florida

  • Investigational Site Number 840056

    Palm Harbor, Florida

  • Investigational Site Number 840089

    Atlanta, Georgia

  • Investigational Site Number 840054

    Lawrenceville, Georgia

  • Investigational Site Number 840119

    Woodstock, Georgia

  • Investigational Site Number 840108

    Idaho Falls, Idaho

  • Investigational Site Number 840075

    Arlington Heights, Illinois

  • Investigational Site Number 840080

    Chicago, Illinois

Showing 40 of 273 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.